Experienced in Glomerulonephritis

Hui Q. Jiang

117 Meishan Road, 
Hefei, CN 
Experienced in Glomerulonephritis
117 Meishan Road, 
Hefei, CN 
OverviewLocationsClinical Research

Overview

Hui Jiang practices in Hefei, China. Ms. Jiang is rated as an Experienced expert by MediFind in the treatment of Glomerulonephritis. Her top areas of expertise are Avian Influenza, Brucellosis, Flu, Lung Transplant, and Endoscopy.

Her clinical research consists of co-authoring 543 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 9 articles in the study of Glomerulonephritis.

Gender
Female

Locations

117 Meishan Road, Hefei, China
Other Locations
Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China
No. 127 Dongming Road, Zhengzhou, 450008, China
866 Yuhangtang Road, Hangzhou, China
Jialuo Road 2019, Jiadingzhen, 201800, China
No. 9 Huangshan South Road, Zhenjiang, 212004, China
Zhangheng Road 239, Pudong, 201204, China
No. 180, Fenglin Rd, Xuhui, 200032, China
The Affiliated Hospital Of Jiangnan University 200 Huihe Road, Wuxi, 214062, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2

543 Total Publications

Prevalence of Schistosoma japonicum infections in wild rodents in key areas during the elimination phase
Prevalence of Schistosoma japonicum infections in wild rodents in key areas during the elimination phase
Journal: Zhongguo xue xi chong bing fang zhi za zhi = Chinese journal of schistosomiasis control
Published: December 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Jiang's expertise for a condition
ConditionClose
    View All 123 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile